There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNTech SE (BNTX – Research Report) and Ayala Pharmaceuticals (AYLA – Research Report) with bullish sentiments.
BioNTech SE (BNTX)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BioNTech SE, with a price target of $298.00. The company’s shares closed last Tuesday at $161.03, close to its 52-week low of $117.08.
According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
BioNTech SE has an analyst consensus of Hold, with a price target consensus of $229.67, representing a 51.7% upside. In a report issued on June 27, Berenberg Bank also maintained a Buy rating on the stock with a $350.00 price target.
Ayala Pharmaceuticals (AYLA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ayala Pharmaceuticals, with a price target of $18.00. The company’s shares closed last Tuesday at $1.09, close to its 52-week low of $0.96.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Ayala Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNTX: